Sharma Pranav, Zargar-Shoshtari Kamran, Sexton Wade J
a Department of Genitourinary Oncology , Moffitt Cancer Center , Tampa , FL , USA.
Expert Rev Anticancer Ther. 2015;15(12):1379-87. doi: 10.1586/14737140.2015.1115350. Epub 2015 Nov 16.
The most effective intravesical regimen for the treatment of non-muscle invasive bladder cancer (NMIBC) refractory to Bacillus Calmette-Guérin (BCG) has still not been identified or optimized to minimize recurrence-free survival and prevent progression reliably and consistently. Valrubicin, however, is a cytotoxic chemotherapeutic agent that is used as an intravesical agent for BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Here we analyze the literature regarding the treatment of non-muscle invasive urothelial malignancies with intravesical valrubicin for refractory bladder cancer, present our opinion on its current clinical impact and speculate on how its utilization will evolve in the near future.
对于卡介苗（BCG）治疗无效的非肌肉浸润性膀胱癌（NMIBC），尚未确定或优化出最有效的膀胱内治疗方案，以可靠且持续地将无复发生存率最大化并预防疾病进展。然而，瓦鲁比星是一种细胞毒性化疗药物，用作膀胱内给药药物，用于那些立即进行膀胱切除术会带来不可接受的发病率或死亡率的患者，治疗卡介苗难治性膀胱原位癌（CIS）。在此，我们分析了关于使用膀胱内瓦鲁比星治疗难治性膀胱癌的非肌肉浸润性尿路上皮恶性肿瘤的文献，阐述了我们对其当前临床影响的看法，并推测其在不久的将来的应用将如何发展。
